NCT00216502View on ClinicalTrials.gov

A Study of the Safety and Effectiveness of Galantamine in Patients With Alzheimer's Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

254

Participants

Timeline

Start Date

August 31, 2001

Study Completion Date

November 30, 2005

Conditions
Alzheimer DiseaseDementiaMental DisordersBrain Diseases
Interventions
DRUG

galantamine hydrobromide

All Listed Sponsors
lead

Janssen-Cilag S.p.A.

INDUSTRY

NCT00216502 - A Study of the Safety and Effectiveness of Galantamine in Patients With Alzheimer's Disease | Biotech Hunter | Biotech Hunter